Loading clinical trials...
Loading clinical trials...
A Phase I, Multi-center, Open-label, Single-arm, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activities of FCN-411 Monotherapy in Advanced Non-small Cell Lung Cancer
Conditions
Interventions
FCN-411 Dose-escalation
FCN-411 Dose-expansion
Locations
1
China
Cancer hospital chinese academy fo medical scienced
Beijing, China
Start Date
August 1, 2018
Primary Completion Date
December 31, 2020
Completion Date
December 20, 2021
Last Updated
July 16, 2020
NCT06066138
NCT05692635
NCT05198830
NCT06498635
NCT06305754
NCT07336732
Lead Sponsor
Ahon Pharmaceutical Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions